PDB22 EVALUATING THE LONG-TERM COST-EFFECTIVENESS OF INSULIN ASPART (NOVORAPID®) VERSUS HUMAN SOLUBLE INSULIN IN PATIENTS WITHTYPE 2 DIABETES IN SPAIN AND ITALY
Abstract
Authors
K Erny-Albrecht G Goodall C Townsend R Kotchie S Nielsen WJ Valentine